Nabriva Therapeutics PLC reports results for the quarter ended in September - Earnings Summary

Nabriva Therapeutics

09/11/2021 22:03

* Nabriva Therapeutics PLC  NBRV.OQ  reported a quarterly
adjusted loss of 2 cents​​ per share for the quarter ended in
September. The mean expectation of three analysts for the
quarter was for a loss of 24 cents per share.
* Revenue rose 586.4% to $8.86 million from a year ago; 
analysts expected $9.50 million. 
* Nabriva Therapeutics PLC's reported EPS for the quarter was a
loss of 2 cents​.
* The mean earnings estimate of analysts had fallen by
about 9.7% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Nabriva Therapeutics PLC shares had risen by 9.2% this
quarter and lost 46.3% so far this year.
* The company reported a quarterly loss of $10.65 million.
* Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $2.68 
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 9 at 10:03 p.m.
 ​All figures in US dollars unless otherwise stated